Salute e Benessere

AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related…

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May22, 2023(GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We are very excited to have initiated this U.S. trial,” said Diane Tang-Liu, PhD, CEO, President & Co-Founder of AiViva...

Nexstim Plc: Managers' Transactions, Hildén

Company Announcement , Helsinki, 22 May 2023 at 12:30PM(EEST) Nexstim Plc: Managers' Transactions, Hildén Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Timo Hildén Position: Member of the Board/Deputy memberIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32104/4/4____________________________________________...

Nexstim Plc: Managers' Transactions, Weckroth

Company Announcement , Helsinki, 22 May 2023 at 12:25PM(EEST) Nexstim Plc: Managers' Transactions, Weckroth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Tero Weckroth Position: Member of the Board/Deputy memberIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32101/4/4...

Nexstim Plc: Managers' Transactions, Forss

Company Announcement , Helsinki, 22 May 2023 at 12:20PM(EEST) Nexstim Plc: Managers' Transactions, Forss Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Martin Forss Position: Member of the Board/Deputy memberIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32098/5/4____________________________________________...

Nexstim Plc: Managers' Transactions, Niemistö

Company Announcement , Helsinki, 22 May 2023 at 12:15PM(EEST) Nexstim Plc: Managers' Transactions, Niemistö Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Leena Niemistö Position: Member of the Board/Deputy memberIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32083/5/4...

Nexstim Plc: Managers' Transactions, Karvinen

Company Announcement , Helsinki, 22 May 2023 at 12:10PM(EEST)Nexstim Plc: Managers' Transactions, Karvinen Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Mikko Karvinen Position: Chief Executive OfficerIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32095/5/6____________________________________________...

A.Menarini Diagnostics announces the release of the PRIME MDx platform

In response to these needs and market dynamics, A.Menarini Diagnostics rose to the challenge and coordinated the development of a brand new solution in record time, relying on the skills of its R&D department with Italian and international partners. In response to these needs and market dynamics, A.Menarini Diagnostics rose to the challenge and coordinated the development of a brand new solution in record time, relying on the skills of its R&D department with Italian and international...

CORVIA MEDICAL RELEASES TWO-YEAR CLINICAL TRIAL RESULTS CONFIRMING SUSTAINED…

"The two-year REDUCE LAP-HF II findings demonstrate the longer-term safety of the Corvia Atrial Shunt and support what we observed at one year, that in properly selected patients, atrial shunting appears to have lasting clinical benefit in the reduction of heart failure events," said Finn Gustafsson, MD, Professor of Cardiology, University of Copenhagen. "This is the first longer-term, randomized data available for any atrial shunt device, and it continues to suggest that heart…

SKAN Research Trust and Quadram Institute Bioscience to collaborate in Gut…

The Quadram Institute Bioscience (QIB) and SKAN Research Trust direct considerable research resources towards addressing gut health and the gut-cardiovascular and gut-brain axes. Important areas on which QIB and SKAN will collaborate under the terms of the Comprehensive Partnership Agreement include: The Quadram Institute Bioscience (QIB) and SKAN Research Trust direct considerable research resources towards addressing gut health and the gut-cardiovascular and gut-brain axes. Important areas…

Nexstim Plc: Managers' Transactions, Juokslahti

Company Announcement , Helsinki, 22 May 2023 at 10:45 AM(EEST) Nexstim Plc: Managers' Transactions, Juokslahti Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Joonas Juokslahti Position: Chief Financial OfficerIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32062/5/6____________________________________________...

Nexstim Plc: Managers' Transactions, Laine

Company Announcement , Helsinki, 22 May 2023 at 10:40 AM(EEST) Nexstim Plc: Managers' Transactions, Laine Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Jarmo Laine Position: Other senior managerIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32081/5/6____________________________________________ Transaction date:...

Nexstim Plc: Managers' Transactions, Hannula

Company Announcement , Helsinki, 22 May 2023 at 10:35 AM(EEST) Nexstim Plc: Managers' Transactions, Hannula Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Henri Hannula Position: Other senior managerIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32077/5/6____________________________________________ Transaction...

Nexstim Plc: Managers' Transactions, Järnefelt

Company Announcement , Helsinki, 22 May 2023 at 10:30 AM(EEST) Nexstim Plc: Managers' Transactions, Järnefelt Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Gustaf Järnefelt Position: Other senior managerIssuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 32080/4/6____________________________________________ Transaction...

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

The study aimed to find small molecular compounds that disrupt the AKAP18d-PLB protein to protein interaction which is specifically found in heart tissue, as this may protect from ischemia reperfusion injury in the treatment of acute myocardial infarction (heart attack). 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump. Targeting the AKAP18d-PLB interaction in this way, prevents the…

Shenzhen SiBionics Co., Ltd. to apply for CE certification for SIBIONICS CGM

In November 2021, an innovative technology medical company in China, Shenzhen SiBionics Co., Ltd.(hereinafter referred to as SiBionics), launched China's first all-in-one calibration-free CGM (Continuous Glucose Monitoring) product - SIBIONICS CGM, which successfully demonstrated its innovation achievements in the field of medical devices. InNovember 2021, an innovative technology medical company inChina, Shenzhen SiBionics Co., Ltd.(hereinafter referred to as SiBionics), launched...

SKF invests in magnetic bearing manufacturing to meet increasing demand

Thomas Fröst, President, Independent & Emerging Business, says: "Magnetic bearings have played a key role in traditional energy segments for many years. As this technology is now playing a central role in green industries, we need to make sure we can maintain our leading position in terms of technical development and customer service. Our new site in Morocco is an important step in this direction." Thomas Fröst, President, Independent & Emerging Business, says: "Magnetic…

TVM Capital Healthcare Announces Euro 10 Million Investment in DEBx Medical

DEBx Medical, founded in 2019, has developed a groundbreaking product, DEBRICHEM®, which offers a superior alternative to existing treatments for non-healing chronic wounds. This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds. With CE and ISO approvals obtained in February 2021, DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market. DEBx Medical, founded in 2019, has...

Roche introduces navify® Sample Tracking for labs to track patient test samples…

With navify® Sample Tracking, lab managers can gain greater control by accessing and combining innovative applications to tailor and scale the solution to meet their lab's unique needs and it helps lab managers monitor and measure diagnostic test sample quality from the start - before samples even reach lab premises. navify Sample Tracking directly interfaces the lab with PPA solution vendors and the laboratories' information system (LIS) and the middleware cobas® infinity lab to provide fast…

IBA signs Binding Term Sheet with Medtechnica Ltd for two Proteus®ONE proton…

Louvain-La-Neuve, Belgium, May 22, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Binding Term Sheet with Medtechnica Ltd for the installation of two Proteus ® ONE 1compact proton therapy solutions at the Sourasky Medical Center (Ichilov Hospital) in Tel Aviv, Israel. Sourasky Medical Center has been selected...

BioSenic provides First Quarter 2023 Business Update

REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023 Ongoing discussions for key partnerships with lead clinical assetsMont-Saint-Guibert, Belgium, May 22 nd, 2023 7 .00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights...

Marketing Authorisation Application for lecanemab submitted in Great Britain…

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...

Oncoclínicas Group records a net revenue of BRL 41 million for Q123

The results are due to a growth in turnover (32.5%), along with acquisitions completed in 2022 and acceleration of cancer center activities. Compared to the previous quarter (Q422), net revenue growth was 6.3% and over the twelve-month period it amounted to BRL 4.6 billion. Net income reached BRL 41 million in the first quarter of this year, and completing three consecutive quarters of growth. The results are due to a growth in turnover (32.5%), along with acquisitions completed in 2022 and...

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results…

Dupixent ®(dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineDupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements...

Cell Isolation Market worth $8.2 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479 Browse in-depth TOC on "Cell Isolation Market" 412 - Tables 46 - Figures 307 - Pages Cell Isolation Market Scope: The consumables segment accounted for the largest share of the product segment in the cell isolation market in 2022. Based on product, the cell...

Altri Comunicati